Hearing Anemia
Before the Blood Draw
A live clinical deployment at Shrimad Rajchandra Medical and Research Institute, Gujarat — applying Sona-2's Large Acoustic Model to non-invasive anemia screening at roughly 100 assessments per day.
Amplifier Health Research · 40-day hospital pilot · Active · 2026
1.6 Billion People.
One Diagnostic Tool.
Anemia is the most prevalent nutritional disorder on earth. The only way to confirm it is a blood draw. In rural, high-volume clinical settings, that bottleneck is the entire problem.
Across rural Gujarat — and much of low-resource India — anemia prevalence reaches 60 to 70% in some regions. It affects maternal health, child development, and workforce productivity at population scale. It is almost entirely preventable with early identification and iron supplementation.
The diagnostic gap isn't a knowledge problem. Every frontline health worker knows anemia is likely. The problem is confirmation. Without a blood draw, you cannot objectively diagnose it. In settings where lab capacity is scarce and patient volume is high, that requirement means cases are missed, under-treated, and under-counted.
"No other biomarker for anemia exists at population scale. You must do a blood draw. That is exactly what we are trying to change."
Amplifier's acoustic model detects physiological correlates of anemia — tissue oxygen deficit, altered respiratory drive, changes in phonation energy — from 20 seconds of prompted speech. No consumables. No needles. Any smartphone. The same screen that takes a blood draw can be preceded by a voice triage that tells the health worker which patients need it most.
Three Forces.
One Clinical Deployment.
A population health crisis, a hospital with the patient volume and infrastructure, and an acoustic model with proven signal direction. The fit was structural.
The anemia program started with a clinical reality that no technology had solved. Amplifier had Sona-2 already demonstrating meaningful sensitivity and specificity against hemoglobin levels across thousands of samples. The question was whether that signal could be deployed in a new clinical environment, with a local patient population, in new languages.
Shrimad Rajchandra Medical and Research Institute, running an active anemia outreach program at roughly 100 patient assessments per day, had the patient volume, the blood draw infrastructure, and the clinical motivation. Amplifier had Sona-2 and a B2C web application localizable to Hindi and Gujarati.
The team structured a label exchange: Amplifier provides session IDs and preliminary model scores; SRMD maps them to hemoglobin values from concurrent CBC draws. That feedback loop is now running and has markedly improved model performance on this population.
Real Patients.
Real Ground Truth.
Early signal from live deployment confirmed what the model was built to detect. Not a formal validation — directionally decisive enough to justify everything that followed.
45 of 60 patients confirmed anemic by WHO criteria
The model flagged elevated risk at a rate consistent with confirmed CBC anemia. Prevalence matched regional epidemiological data. Signal direction confirmed.
Model performance markedly improved post fine-tune
Weekly label exchange with SRMD has continuously improved Sona-2's performance. Calibration to Gujarati and Hindi speech patterns is ongoing as the dataset grows.
Gujarati and Hindi · CBC hemoglobin (g/dL)
Both local languages deployed in production. Ground truth is concurrent CBC hemoglobin from the same clinical visit, matched by session ID — no workflow change required.
This phase established signal direction and initiated the fine-tuning loop — not to report clinical performance metrics. Sensitivity and specificity will be established at the 300-session blinded evaluation threshold.
The Validation Study.
Now Underway.
Live deployment. Real patients. Concurrent ground truth. The calibration dataset is being assembled at 100 sessions per day.
Screen. Refer. Treat.
Three stages. One pathway from first contact to confirmed intervention — with voice replacing the blood draw at the triage layer.
How Sona-2 Reads
Anemia in Voice
Five stages from raw audio to clinically actionable triage output. No blood required at any point in the pipeline.
One Playbook.
Every High-Prevalence Geography.
This pilot is the proof point that unlocks a recurring screening contract, a public grant, and a replicable deployment template for any population on earth.
Why this market is structurally different
Every competing approach requires a blood draw, a finger stick, or specialized hardware. Sona-2 requires none of these. The barrier to deployment is a smartphone and 20 seconds of speech. That asymmetry doesn't erode — it compounds with each new language and geography.
What a validated pilot unlocks
A direct screening contract at approximately 6 million assessments annually with the existing clinical partner. A public grant that funds continued development. And a deployment template — the same fine-tuning pipeline and label exchange protocol, replicable to any high-prevalence population in any language.
The commercial model is per-organization screening contracts — cloud-based, hardware-agnostic, no EHR required. De-identified, federated. No raw audio leaves the facility.
Three Milestones.
One Clear Path.
The pilot is active. The label exchange is running. These are the near-term gates from calibration to deployment at scale.